• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by JIN MEDICAL INTERNATIONAL LTD.

    8/20/25 5:15:40 PM ET
    $ZJYL
    Industrial Specialties
    Health Care
    Get the next $ZJYL alert in real time by email

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of August 2025

     

    Commission File Number: 001-41661

     

    JIN MEDICAL INTERNATIONAL LTD.

    (Exact name of registrant as specified in its charter)

     

    No. 33 Lingxiang Road, Wujin District

    Changzhou City, Jiangsu Province

    People’s Republic of China

    (Address of Principal Executive Office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒      Form 40-F ☐

     

     

     

     

     

    INCORPORATION BY REFERENCE

     

    This report on Form 6-K (“Report”) shall be deemed to be incorporated by reference into the registration statement on F-3 (File No. 333-288314) of Jin Medical International Ltd., a Cayman Islands exempted company (the “Company”) filed with the U.S. Securities and Exchange Commission June 25, 2025), (“Registration Statement”), and into each prospectus or prospectus supplement outstanding under the Registration Statement, to the extent not superseded by documents or reports subsequently filed or furnished by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

     

    EXPLANATORY NOTE

     

    The Company is furnishing this current report on Form 6-K to provide its unaudited condensed consolidated financial statements for the six months ended March 31, 2025, attached as Exhibit 99.1 to this report of foreign private issuer on Form 6-K,. and Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended March 31, 2025 is attached as Exhibit 99.2 to this report of foreign private issuer on Form 6-K

     

    SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

     

    This Form 6-K Report and the exhibits hereto contain certain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “assesses,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or similar expressions.

     

    Many of these statements are based on our assumptions about factors that are beyond our ability to control or predict and are subject to significant risks and uncertainties that are described more fully in “Item 3. Key Information-D. Risk Factors” on our annual report on Form 20-F filed with the SEC on January 24, 2025. Any of these factors or a combination of these factors could materially affect our future results of operations and the ultimate accuracy of the forward-looking statements. Fluctuations in our future financial results may negatively impact the value of our Class A ordinary shares. In addition to these important factors, important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include, among other things:

     

    ●assumptions about our future financial and operating results, including revenue, income, expenditures, cash balances, and other financial items;

     

    ●our ability to execute our growth, and expansion, including our ability to meet our goals;

     

    ●current and future economic and political conditions;

     

    ●our capital requirements and our ability to raise any additional financing which we may require;

     

    ●our ability to attract clients and further enhance our brand recognition;

     

    ●our ability to hire and retain qualified management personnel and key employees in order to enable us to develop our business;

     

    ●trends and competition in the education industry;

     

    ●other assumptions described in this Report underlying or relating to any forward-looking statements.

     

    1

     

     

    Should one or more of the foregoing risks or uncertainties materialize, should any of our assumptions prove incorrect, or should we be unable to address any of the foregoing factors, our actual results may vary in material and adverse respects from those projected in these forward-looking statements. Consequently, there can be no assurance that actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects, on us. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements.

     

    The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s annual report and other filings with the U.S. Securities and Exchange Commission. As a result, you are cautioned not to rely on any forward-looking statements.

     

    Financial Statements and Exhibits.

     

    Exhibits:

     

    Exhibit No.   Description
    99.1   Unaudited Condensed Consolidated Financial Statements as of March 31, 2024 and for the Six Months Ended March 31, 2025 and 2024.
    99.2   Operating and Financial Review and Prospects in Connection with the Unaudited Condensed Consolidated Financial Statements for the Six Months March 31, 2025 and 2024.
    101.INS   Inline XBRL Instance Document
    101.SCH   Inline XBRL Taxonomy Extension Schema Document.
    101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
    101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
    101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
    101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
    104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Jin Medical International Ltd.
         
    Date: August 20, 2025 By: /s/ Erqi Wang
        Erqi Wang
        Chief Executive Officer

     

      By: /s/ Ziqiang Wang
        Ziqiang Wang
        Chief Financial Officer

     

    3

     

    Jin Medical International Ltd.
    Get the next $ZJYL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZJYL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ZJYL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Jin Medical Launches Production at Plant No. 3, Accelerating Global Delivery from the Chuzhou Manufacturing Facility

    Beijing, China, July 15, 2025 (GLOBE NEWSWIRE) -- Jin Medical International Ltd. (NASDAQ:ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a Nasdaq-listed provider of rehabilitation medical equipment, announced today that its wholly owned subsidiary, ZhongJin Medical Equipment (Anhui) Co., Ltd. ("Zhongjin Anhui"), has officially launched production at Plant No. 3 of Zhongjin Anhui's intelligent manufacturing facility in Chuzhou, Anhui, China. With 19 years of expertise in rehabilitation technology, the Company is committed to accelerate the integration of the global rehabilitation device supply chain through its robust production and precision manufacturing cap

    7/15/25 9:00:00 PM ET
    $ZJYL
    Industrial Specialties
    Health Care

    Jin Medical International Ltd. – Nasdaq Minimum Bid Price Non-Compliance

    Changzhou City, China, May 06, 2025 (GLOBE NEWSWIRE) -- Jin Medical International Ltd. (NASDAQ:ZJYL) (the "Company") today announced that on May 2, 2025, it received a deficiency letter (the "Notice") from the Nasdaq Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"). The Notice informed the Company that, based upon the closing bid price of the Company's ordinary shares ("Ordinary Shares") over the 30 consecutive business day period between March 20, 2025 and May 1, 2025, the Company is not in compliance with the requirement to maintain a minimum bid price of $1.00 per share of its Ordinary Shares for continued listing on The Nasdaq Capital Market, as

    5/6/25 4:10:00 PM ET
    $ZJYL
    Industrial Specialties
    Health Care

    Construction of JinMed's New Facility Begins in Chuzhou, China

    Chuzhou City, China, Oct. 10, 2024 (GLOBE NEWSWIRE) -- JIN MEDICAL INTERNATIONAL LTD. (the "Company" or "JinMed") (NASDAQ:ZJYL), an industrial leader in Assistive Technologies ("AT"), and a manufacturer and developer of wheelchairs and living aids products, today announced the initiation of construction of JinMed's new manufacturing facility at Chuzhou City, Anhui Province, China. JinMed (Anhui) Co., Ltd., a newly established subsidiary of JinMed, will be designated to operate the Chuzhou JinMed plant (the "New Facility") which is established as an internationally standardized, innovative, and high-end wheelchair and electric wheelchair manufacturing factory. With higher-level production l

    10/10/24 8:00:00 AM ET
    $ZJYL
    Industrial Specialties
    Health Care

    $ZJYL
    SEC Filings

    View All

    SEC Form EFFECT filed by JIN MEDICAL INTERNATIONAL LTD.

    EFFECT - Jin Medical International Ltd. (0001837821) (Filer)

    9/10/25 12:15:12 AM ET
    $ZJYL
    Industrial Specialties
    Health Care

    Amendment: SEC Form F-3/A filed by JIN MEDICAL INTERNATIONAL LTD.

    F-3/A - Jin Medical International Ltd. (0001837821) (Filer)

    9/3/25 3:31:26 PM ET
    $ZJYL
    Industrial Specialties
    Health Care

    SEC Form 6-K filed by JIN MEDICAL INTERNATIONAL LTD.

    6-K - Jin Medical International Ltd. (0001837821) (Filer)

    8/20/25 5:15:40 PM ET
    $ZJYL
    Industrial Specialties
    Health Care

    $ZJYL
    Financials

    Live finance-specific insights

    View All

    Jin Medical International Limited (NASDAQ: ZJYL) Announces Financial Results for Six Months Ended March 31, 2023

    CHANGZHOU, China, Aug. 23, 2023 /PRNewswire/ -- Jin Medical International Limited ("the Company" or "JinMed") (NASDAQ:ZJYL), a Cayman Islands holding company with Chinese operating entities that manufacture and develop wheelchairs and living aids products, today announced its financial results for the six months ended March 31, 2023 ("the period"). Financial and Operational Highlights for Six Months Ended March 31, 2023 Revenues were $10.25 million, representing an 8.3% increase from $9.47 million for the first six months ended March 31, 2022.Revenues from wheelchair products were $8.38 million, an increase of 5.4% from $7.95 million for the six months ended March 31, 2022.Revenues from whee

    8/23/23 4:15:00 PM ET
    $ZJYL
    Industrial Specialties
    Health Care